BioLife Solutions, Inc.
BLFSNASDAQHealthcare● Active
$26.45
$-0.20(-0.74%)
Market Cap$1.3B
P/E Ratio—
52W High$29.62
52W Low$17.86
BioLife Solutions, Inc. (BLFS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BLFS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.04
Est. $0.01 · +300.0%
Revenue
$0.03B
Est. $0.03B · +7.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
BLFS reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.03 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.01 | $0.04 | +300.0% | $0.03B | $0.03B | +7.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.02 | $0.04 | +300.0% | $0.02B | $0.02B | +2.9% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.00 | $0.04 | +1900.0% | $0.03B | $0.03B | +9.3% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.03 | -$0.33 | -888.5% | $0.03B | $0.03B | -1.1% |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.05 | $0.04 | +182.4% | $0.02B | $0.02B | +7.7% |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.06 | -$0.01 | +83.3% | $-0.00B | $0.02B | -115.7% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.08 | -$0.02 | +74.5% | $0.03B | $0.02B | +41.9% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.04
EPS Est.
$0.01
EPS Surpr.
+300.0%
Revenue
$0.03B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.04
EPS Est.
-$0.02
EPS Surpr.
+300.0%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.04
EPS Est.
$0.00
EPS Surpr.
+1900.0%
Revenue
$0.03B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.03
EPS Surpr.
-888.5%
Revenue
$0.03B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.05
EPS Surpr.
+182.4%
Revenue
$0.02B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.06
EPS Surpr.
+83.3%
Revenue
$-0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.02
EPS Est.
-$0.08
EPS Surpr.
+74.5%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.09 | $0.09 | $0.10 | 1 |
| Q3 FY2027 | $0.08 | $0.09 | $0.09 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +300.0% | $21.75 | $23.12 | +6.30% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +300.0% | $22.47 | $22.48 | +0.04% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +1900.0% | $27.57 | $27.02 | -1.99% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -888.5% | $21.09 | $20.64 | -2.13% |
| ▲ Q2 FY2025 | May 8, 2025 | +182.4% | $21.34 | $22.36 | +4.78% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +83.3% | $24.00 | $24.51 | +2.13% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +74.5% | $26.60 | $26.50 | -0.38% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +56.6% | $22.05 | $22.74 | +3.13% |
Q2 FY2026+6.30%
Report Date
May 7, 2026
EPS Beat/Miss
+300.0%
Price Before
$21.75
Price After
$23.12
Q1 FY2026+0.04%
Report Date
Feb 26, 2026
EPS Beat/Miss
+300.0%
Price Before
$22.47
Price After
$22.48
Q4 FY2025-1.99%
Report Date
Nov 6, 2025
EPS Beat/Miss
+1900.0%
Price Before
$27.57
Price After
$27.02
Q3 FY2025-2.13%
Report Date
Aug 7, 2025
EPS Beat/Miss
-888.5%
Price Before
$21.09
Price After
$20.64
Q2 FY2025+4.78%
Report Date
May 8, 2025
EPS Beat/Miss
+182.4%
Price Before
$21.34
Price After
$22.36
Q1 FY2025+2.13%
Report Date
Mar 3, 2025
EPS Beat/Miss
+83.3%
Price Before
$24.00
Price After
$24.51
Q4 FY2024-0.38%
Report Date
Nov 12, 2024
EPS Beat/Miss
+74.5%
Price Before
$26.60
Price After
$26.50
Q3 FY2024+3.13%
Report Date
Aug 8, 2024
EPS Beat/Miss
+56.6%
Price Before
$22.05
Price After
$22.74
Avg Beat Reaction+2.00%
Avg Miss Reaction-2.13%
Beat Rate7 / 8 quarters
Largest Move+6.30% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BLFS ends December
BioLife Solutions, Inc. (BLFS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.04 — beating the analyst consensus of $0.01 by +300.0%. BLFS has beaten EPS estimates for 3 consecutive quarters. The next BLFS earnings date is expected around September 1, 2026.
Each quarter, investors track BLFS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BLFS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BLFS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BLFS earnings · 5 questionsBioLife Solutions, Inc.'s next earnings report is expected around September 1, 2026. BLFS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BLFS historically reports after market close (AMC).
BLFS earnings datewhen is BLFS earningsBLFS next earnings datewhen does BLFS report earningsBLFS earnings calendar
▸ Source: FMP · BioLife Solutions, Inc. SEC filings · US GAAP · BioLife Solutions, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026